THE FUTURE IS NOW

Yesterday’s dreams are today’s reality and tomorrow’s memories.
At GaiaCell, we are committed to evolution and continual development at the convergence of life sciences, medicine, the pharma industry, and ethics. For a quarter of a century, generations of GaiaCell researchers and developers have been educating not only professionals and the general public but, above all — ourselves. By following our dreams and sharing them with humankind, we are developing new advanced therapies and providing them to those who need them. All our work is based on core ethical values that are the foundation of all that Educell does and is committed to.
Dreams allowed!

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANISATION (CDMO)

GaiaCell is a contract development and manufacturing organisation (CDMO) operating in the field of cell-based therapeutics. The development of our own products, which have been successfully employed in clinics, provided us with crucial knowledge and experience that can be employed in future projects. We are collaborating with a strategic partner for the development of point-of-care (POC) networks, cell- and gene-based therapeutics, and technological platforms for use in cancer immunotherapy.

The production of cell preparations takes place in clean rooms designed and maintained according to GMP (Good Manufacturing Practice) guidelines. Class B clean rooms are equipped with laminar airflow hoods (cleanliness class A) in which key production steps take place. During the entire production process, we ensure quality control of intermediate and final products in accordance with the guidelines and the European Pharmacopoeia.

News from the world of advanced treatments

In vitro models for adipose tissue engineering with adipose-derived stem cells using different scaffolds of natural origin

Girandon L, Kregar-Velikonja N, Božikov K, Barlič A.
Folia Biol (Praha). 2011;57(2):47-56.

VEČ

Primary human alveolar bone cells isolated from tissue samples acquired at periodontal surgeries exhibit sustained proliferation and retain osteogenic phenotype during in vitro expansion

Marolt D, Rode M, Kregar-Velikonja N, Jeras M, Knezevic M.
PLoS One. 2014 Mar 25;9(3): e92969.

VEČ

Cell sources for nucleus pulposus regeneration

Kregar Velikonja N, Urban J, Fröhlich M, Neidlinger-Wilke C, Kletsas D, Potočar U, Turner S, Roberts S.
Eur Spine J 23, 364–374 (2014).

VEČ
crossmenu